SCHEMBL1372326

SCHEMBL1372326

CC(C)(C)OC(=O)N1C[C@H](Cc2ccc(F)c(F)c2)C[C@H]1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 3/20 0.40
NR1H3 Q13133 3/20 0.40
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
P2RX3 P56373 1/20 0.38
CCR3 P51677 1/20 0.37
DPP4 P27487 1/20 0.37
HTRA1 Q92743 1/20 0.37
TSHR P16473 1/20 0.36
ACE P12821 1/20 0.36
TGM2 P21980 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
OPRK1 P41145 1/20 0.36
BCL9 O00512 1/20 0.35
CTNNB1 P35222 1/20 0.35
HSD11B1 P28845 1/20 0.35
AGTR2 P50052 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2173029 1.00 NR1H2 (0.40) NR1H2NR1H3CYP1A2POLBCYP3A4
SCHEMBL23452241 0.92 OPRK1 (0.40) NR1H2NR1H3CYP1A2POLBCYP3A4
SCHEMBL29202468 0.92 OPRK1 (0.40) NR1H2NR1H3CYP1A2POLBCYP3A4
SCHEMBL29202470 0.92 OPRK1 (0.40) NR1H2NR1H3CYP1A2POLBCYP3A4
SCHEMBL24645468 0.91 CA1 (0.40) P2RX3CCR3TLR7
SCHEMBL1371619 0.89 CCR3 (0.43) NR1H2NR1H3CYP3A4CCR3AGTR2
SCHEMBL2171252 0.89 CCR3 (0.43) NR1H2NR1H3CYP3A4CCR3AGTR2
SCHEMBL29036351 0.89 CCR3 (0.43) NR1H2NR1H3CYP3A4CCR3AGTR2
SCHEMBL1373064 0.87 NR1H2 (0.43) NR1H2NR1H3CYP1A2POLBCYP3A4
SCHEMBL21409216 0.87 NR1H2 (0.43) NR1H2NR1H3CYP1A2POLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791102-B2 Acetanilide sphingosine-1-phosphate receptor antagonists EXELIXIS, INC. (US) 2014-07-29 US disclosed
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists EXELIXIS, INC. (US) 2011-11-24 US disclosed
EP-2346821-A1 SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS Exelixis, Inc. (US) 2011-07-27 EP disclosed
WO-2010045580-A1 SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS EXELIXIS, INC. (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists S1PR1, S1PR2, S1PR3 NR1H2 253/4885NR1H3 287/4885CYP1A2 4844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.